D. Cooper

Publications831
h-index104
Citations49,028
Highly Influential Citations1,521
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Kelleher
  • 293 Publications • 14,425 Citations
  • A. Carr
  • 234 Publications • 19,268 Citations
  • S. Emery
  • 223 Publications • 11,387 Citations
  • D. Richman
  • 689 Publications • 78,110 Citations
  • Publications
  • Influence
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
Objective:To describe a syndrome of peripheral lipodystrophy (fat wasting of the face, limbs and upper trunk), hyperlipidaemia and insulin resistance in patients receiving potent HIV protease… Expand
  • 2,338
  • 72
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study
BACKGROUND The prevalence and severity of lipodystrophy syndrome with long-term therapy for HIV-1 infection that includes a protease inhibitor is unknown. We studied the natural course of the… Expand
  • 1,590
  • 68
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
BACKGROUND Data from randomized trials are lacking on the benefits and risks of initiating antiretroviral therapy in patients with asymptomatic human immunodeficiency virus (HIV) infection who have a… Expand
  • 1,732
  • 51
  • PDF
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
OBJECTIVE To update recommendations for antiretroviral therapy for adult human immunodeficiency virus type 1 (HIV-1) infection, based on new information and drugs that are available. PARTICIPANTS A… Expand
  • 1,083
  • 40
  • PDF
Adverse effects of antiretroviral therapy
Antiretroviral toxicity is an increasingly important issue in the management of HIV-infected patients. With the sustained major declines in opportunistic complications, HIV infection is a more… Expand
  • 1,070
  • 40
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
OBJECTIVE New information warrants updated recommendations for the 4 central issues in antiretroviral therapy: when to start, what drugs to start with, when to change, and what to change to. These… Expand
  • 755
  • 34
  • PDF
Characterization of CD4+ CTLs Ex Vivo1
The cytotoxic potential of CD8+ T cells and NK cells plays a crucial role in the immune response to pathogens. Although in vitro studies have reported that CD4+ T cells are also able to mediate… Expand
  • 518
  • 33
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
BACKGROUND The continuing, randomised, multinational, phase IIB POWER 1 and 2 studies aim to evaluate efficacy and safety of darunavir in combination with low-dose ritonavir in treatment-experienced… Expand
  • 470
  • 27
  • PDF
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
BACKGROUND We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1… Expand
  • 520
  • 26
  • PDF
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
Getting HIV Under Control Approximately 1 in 300 people infected with HIV are HIV “controllers” who are able to maintain long-term control of the virus without medication and who do not progress to… Expand
  • 977
  • 25
...
1
2
3
4
5
...